Overview

The Safety and Effectiveness of 524W91

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.

Phase:

Phase 1

Details

Lead Sponsor:

Glaxo Wellcome

Treatments:

Emtricitabine